⭐️ #CancerSymposium speaker spotlight: Adrienne Cox, PhD @unclineberger.bsky.social. Cox is a cancer cell biologist experienced in biochemical, molecular and cellular approaches to RAS superfamily-mediated signaling and transformation. Join us on Friday, 11/20 ➡️ bit.ly/CCSymposium26

#CancerResearch Spotlight: Lead author @jennyhogstrom.bsky.social and senior author @tarumur.bsky.social uncovered new cellular mechanisms that could influence future therapies for hormone receptor positive (HR+) #breastcancer. 📝 @science.org Read more ➡️ bit.ly/4zb754K

A noncanonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer

Resistance to standard-of-care therapies remains a major clinical challenge in the treatment of the most common breast cancer, the hormone receptor–positive (HR+) subtype. Cyclin-dependent kinase 4/6 ...

bit.ly

🩷 What a strong kick-off to #BreastCancerAwarenessMonth! We met with employees at MFS to share information on #breastcancer risk factors and screening options. We also were a proud healthcare sponsor of the @americancancersoc.bsky.social Making Strides Against Breast Cancer walk.

#ASTRO26: Theodore (Ted) Hong, MD shares phase III trial results of protons vs photons for patients with advanced #HCC. Hypothesis: Protons would be more beneficial due to favorable dose distributions and the ability to spare non-target tissue. 💡Proton therapy did not improve OS, PFS, LP, or AEs.

September is #ProstateCancer Awareness Month 💙 Aria Olumi, MD and David Einstein, MD share recommendations on when to begin prostate screening and what to expect during the process. 🩺 Talk to your doctor about whether prostate cancer screening is right for you, especially if you have risk factors.

🏆 Congratulations to our Cancer Research Institute's "Best Papers of 2025" award winners! - Basic science: @ptrt.bsky.social - Translational science: Wenyi Wei, PhD - Clinical science: Cristiana Pineda, MD, PhD - Collaborative science: Frank Slack, PhD @tarumur.bsky.social #CancerResarch

📅 We're almost two months away from our #CancerSymposium! Join colleagues across medicine, research, and biotech to discover the latest advances in the oncology field. From expert-led talks to networking opportunities - explore the future of cancer. Register➡️ bit.ly/CCSymposium26

BIDMC Cancer Center Annual Symposium

Eventbrite - BIDMC Cancer Center presents BIDMC Cancer Center Annual Symposium - Friday, November 20, 2026 at Joseph B. Martin Conference Center, Boston, MA. Find event and ticket information.

bit.ly

Congrats to Kipp Weiskopf, MD, PhD and study co-leads Carlota Pagès Geli, PhD and Juliano Rubeiro, PhD on their paper in @nature.com! The study describes a new approach, Tactical Surfaceome Profiling, to identifying antigens with therapeutic potential in B-cell #lymphoma. More ➡️ bit.ly/3VmL1FC

High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma - Nature Communications

B-cell lymphomas can resist macrophage-mediated phagocytosis through different mechanisms. Here the authors present the results of a high-throughput system to screen for antibodies enhancing macrophag...

bit.ly

Live from our Cancer Research Institute seminar series: Roger Greenberg, MD, PhD, shares how molecular patterns link DNA damage and immune responses. The room is full of excitement and curiosity as we kick off the beginning of the academic year! #CancerResearch #CancerBiology #Genomics

⭐ Congratulations to @jingyiwu.bsky.social for receiving a research grant from @thevfoundation.bsky.social! This research aims to discover what makes a #glioma tumor resist the FDA-approved IDH inhibitor vorasidenib and whether a secondary therapy can improve its response to treatment.

Mark your calendars for the 19th annual BIDMC Cancer Center Symposium! 🗓️ Friday, November 20th, 2026 ⏲️ 9 AM - 5 PM 📍 Joseph B. Martin Conference Center 🎟️ Free registration Register today➡️ bit.ly/CCSymposium26 #CancerSymposium

🧬 #CancerResearch spotlight: Annalisa Di Ruscio, MD, PhD with colleagues from BIDMC and other institutions demonstrate how an RNA-mediated mechanism controls the initiation of DNA replication. The findings may have therapeutic potential for diseases involving abnormal DNA replication. 📝 @nature.com

📰 Dr. David McDermott, Chief, Medical Oncology @BIDMChealth comments on the future of cancer vaccines following news from Moderna and Merck this week about successful phase III trial results of a personalized messenger #RNA #melanoma treatment. Read more in @bostonglobe.com: bit.ly/4zzzoLq

Moderna just made a huge leap forward in the world of cancer vaccines. Here’s what to know. - The Boston Globe

In addition to melanoma, Moderna and Merck are conducting trials with personalized injections to fight types of bladder, kidney, and lung cancers.

bit.ly

🎉 Congratulations to our very own Dr. Ann Kim for graduating from the @ash.hematology.org Hematology-Focused Fellowship Training Program (HFFTP)! We're proud to celebrate this important milestone and look forward to Dr. Kim's continued contributions to the future of #hematology.

📷 @alextoker.bsky.social, co-organizer for @faseborg.bsky.social "Cell Signaling in Cancer" joins members of his lab at this year's conference. The Toker lab presented a range of new scientific discoveries. And shout out to @piskounovalab.bsky.social for helping co-organize this year's event!

❔ What do gray hair and #melanoma have in common? In her latest article for Science in the News, Isabella del Priore @harvardmed.bsky.social explores a scientific discovery linking gray hair and melanoma through cellular signals originating from the same gene, TP53. Read more ➡️ bit.ly/3T1NhkM

Flipping the Switch: Towards hair graying or skin cancer?

Gray hair is accepted—or dreaded—as a universal fate. When hair turns gray, it reflects changes in our biology, such as a particularly stressful period of time or the natural result of aging. Recently...

bit.ly

⭐️ Congrats to Jan Heng, PhD for receiving a Frontiers Program Award from the Massachusetts Life Sciences Center! Her research will investigate how estrogen therapy alters the mechanisms of #breastcancer and #prostatecancer development in individuals carrying BRCA2.

💡 "Leadership is cultivated in the small, daily decisions about how you show up for your team, how you handle difficulty, and how intentionally you invest in your own growth." @chaewonhwangmd.bsky.social

Chaewon Hwang, M.D.@chaewonhwangmd.bsky.social · 3mo ago

Now live on #ASCOConnection! Thank you @ascocancer.bsky.social and @ASCOTECAG for planning this session during #ASCO26 Beyond the Clinic: Building Leadership Skills in Training and Early Career | ASCO Connection connection.asco.org/do/beyond-cl... @bidmc-cancercenter.bsky.social

🩸 Can you predict venous thromboembolism (VTE) in a patient with cancer before a blood clot forms? Researchers at BIDMC like @ioavlachos.bsky.social and collaborators used plasma proteomics to develop a predictive model for VTE and uncovered IL-17 as a potential therapeutic target. 📝 @science.org

❔ How is #cervicalcancer care evolving? 🎙️ Dr. Meghan Shea, medical oncologist and disease program leader at BIDMC joins Ursula Matulonis, MD @danafarber.bsky.social on @onclive.bsky.social to discuss advances in cervical cancer treatments like immunotherapy and ADCs. Listen➡️ bit.ly/4vQcQ6f

❓ Do all BRCA1-mutant tumors develop the same way? Namrata Nilavar, PhD, Postdoc Fellow, BIDMC, presented her research at the 2026 @acscan.bsky.social Breakfast in Boston. Her work suggests distinct BRCA1 mutations may drive different patterns of genomic instability and tumor growth. #CancerResearch

Check out our recap of the episodes of OncLive On Air that aired in May 2026. @mpishvaian.bsky.social @bidmc-cancercenter.bsky.social @mskcancercenter.bsky.social @mdanderson.bsky.social @danafarber.bsky.social @ohsuknight.bsky.social #oncology #hematology www.onclive.com/view/revisit...

Revisit Every OncLive On Air Episode From May 2026 | OncLive

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

onclive.com

Live from our Cancer Research Institute seminar series: Shomit Sengupta, PhD; VP, Biology at Atavistik Bio. Sengupta leads efforts to identify novel targets for rare metabolic and hematology diseases, leveraging nutrient-sensing for drug discovery. #CancerResearch #BioTech

⭐️ Congratulations to @chaewonhwangmd.bsky.social and team for earning this outstanding achievement from @graspcancer.bsky.social! Selected by patient advocates, this award honors research with the potential to improve the lives of patients with cancer #ASCO26. #LungCancer #NSCLC

Chaewon Hwang, M.D.@chaewonhwangmd.bsky.social · 4mo ago

Deeply honored to receive the #GRASPAdvocateChoiceAward, for our work presented at #ASCO26, www.asco.org/abstracts-pr.... Grateful for my collaborators, especially Jason Jincong Freeman, PhD, and mentor Kathryn Huber, MD PhD. I am excited to share this work with patient advocates 6/11/26!

Nadine Tung, MD Marija Sullivan, MD, Mariana Chavez MacGregor, MD Ana Elisa Lohmann #ASCO26 @ascocancer.bsky.social

🧬 Nadine Tung, MD moderated a cancer genetics session #ASCO26. Key takeaways: • Some BRCA2 variants may affect #prostatecancer outcomes • Prostate cancer genetic risk assessment is evolving • PSA + MRI help prostate cancer detection in men w/BRCA2 • The role of GLP-1s in cancer prevention is unclear

❔ Why might immunotherapy work well for one patient but not another with the same cancer? 💡 Dr. Bockorny, GI medical oncologist at BIDMC, highlights how a chromatin regulator mutation (KMT2C) could serve as a predictive biomarker and inform who will respond to immunotherapy in GI cancers #ASCO26

“Insurance and facility type significantly influenced overall survival (OS), highlighting persistent access-related disparities and the need for targeted interventions to promote equitable care.” #ASCO26

Chaewon Hwang, M.D.@chaewonhwangmd.bsky.social · 4mo ago

Excited to share our #RealWorldData and evidence on socioeconomic and clinical factors associated with OS in patients with Stage III #NSCLC following #chemoRT in the post-PACIFIC era! Stop by, 9am-12pm, 5/30! #ASCO2026 #LungCancer @ascocancer.bsky.social @bidmc-cancercenter.bsky.social @TuftsMedCtr

📸 Cancer Research Institute seminar recap: Shengfang Jin, PhD, President and CEO, ENSEM Therapeutics — “ETX-636, a Next-Generation Allosteric Pan-Mutant-Selective PI3Kα Dual Inhibitor and Degrader for the Treatment of PIK3CA-Mutant Diseases.” #CancerResearch #PrecisionMedicine #ComputationalBiology

⌛️ We are two days away from #ASCO26! From translational science to clinical advances, BIDMC oncologists are presenting new research at the @ascocancer.bsky.social annual meeting that will help shape the future of cancer care. We'll see you in Chicago!